Sakar Healthcare signs oncology supply pact with Zydus; stock jumps 33% in 5 days

Sakar Healthcare Ltd. informed exchanges on Wednesday that it has signed its 40th global anti-cancer products agreement with Zydus Lifesciences to supply oncology products to GCC countries and other emerging markets, as the company continues to expand its international business footprint.

Anticipating the development and recent business momentum, Sakar Healthcare shares have surged nearly 33% in the last five trading sessions, rising from ₹592 to ₹789.

In its exchange filing, the company said the agreement with Zydus Lifesciences strengthens its oncology business expansion strategy across global markets. The company added that the latest agreement marks its 40th anti-cancer products partnership globally.

Sakar Healthcare also highlighted progress in its European regulatory pipeline. The company said it has filed 23 Marketing Authorisation (MA) applications in the European Union, out of which five approvals have already been secured and eight have been filed by its partner in Bulgaria. The remaining applications have been submitted across Czech Republic, Croatia and Poland.

Additionally, the company said it has independently applied for 13 new MA approvals in the EU.

The filing further stated that Sakar has made significant regulatory progress with 33 site variation submissions involving major pharmaceutical companies across the UK and Europe. These include partnerships with Accord Healthcare Limited (UK), Heumann Pharma GmbH & Co. Generica KG-Germany, Torrent Pharma UK, Tillomed Laboratories Ltd.-UK and several others.

According to the company, the approvals pipeline currently includes five site variation approvals — three by the European Medicines Agency (EMA) and two by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Sakar Healthcare also said its backward integration strategy is gaining traction, with 21 APIs developed in-house, including 16 with Written Confirmation and two CEP approvals already secured.

Managing Director Sanjay Shah said the company remains focused on strengthening regulatory capabilities, expanding across global markets and scaling operations to enhance market share and drive future earnings growth.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice.